inclusion criteria: * age ≥ 18 years * infection with sars-cov-2 (virus detection by means of a pcr test not older than 72 hours) * bipulmonary infiltrates (detection by means of x-rays or computed tomography) * covid inflammation score ≥ 10 * ferritin concentration (serum or plasma) ≥ 500 ng / ml * arterial oxygen saturation ≤ 93% when breathing room air * written informed consent from the patient * potentially childbearing women: negative pregnancy test exclusion criteria (in medical history): contraindications study medication: * hypersensitivity to the active substance infliximab (or any of the other ingredients of the medicine) or to other murine proteins * active or latent tuberculosis * acute or chronic hepatitis b * severe infections such as invasive fungal infections, bacterial sepsis, or abscesses * opportunistic infections (e.g. pneumocystosis, listeriosis) * moderate or severe heart failure (nyha class iii / iv) * immunosuppression (e.g. organ transplantation, aids, leukopenia) * malignancies or lymphoproliferative diseases or chemotherapy within the last 4 weeks * multiple sclerosis or peripheral demyelinating diseases, including the guillain-barré syndrome * treatment with other biologics for therapy for approved indications of infliximab (e.g. for rheumatoid arthritis, crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis) further

inclusion criteria: * age ≥ 18 years * infection with sars-cov-2 (virus detection by means of a pcr test not older than 72 hours) * bipulmonary infiltrates (detection by means of x-rays or computed tomography) * covid inflammation score ≥ 10 * ferritin concentration (serum or plasma) ≥ 500 ng / ml * arterial oxygen saturation ≤ 93% when breathing room air * written informed consent from the patient * potentially childbearing women: negative pregnancy test exclusion criteria (in medical history): contraindications study medication: * hypersensitivity to the active substance infliximab (or any of the other ingredients of the medicine) or to other murine proteins * active or latent tuberculosis * acute or chronic hepatitis b * severe infections such as invasive fungal infections, bacterial sepsis, or abscesses * opportunistic infections (e.g. pneumocystosis, listeriosis) * moderate or severe heart failure (nyha class iii / iv) * immunosuppression (e.g. organ transplantation, aids, leukopenia) * malignancies or lymphoproliferative diseases or chemotherapy within the last 4 weeks * multiple sclerosis or peripheral demyelinating diseases, including the guillain-barré syndrome * treatment with other biologics for therapy for approved indications of infliximab (e.g. for rheumatoid arthritis, crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis) further

inclusion criteria: - age ≥ 18 years - infection with sars-cov-2 (virus detection by means of a pcr test not older than 72 hours) - bipulmonary infiltrates (detection by means of x-rays or computed tomography) - covid inflammation score ≥ 10 - ferritin concentration (serum or plasma) ≥ 500 ng / ml - arterial oxygen saturation ≤ 93% when breathing room air - written informed consent from the patient - potentially childbearing women: negative pregnancy test exclusion criteria (in medical history): contraindications study medication: - hypersensitivity to the active substance infliximab (or any of the other ingredients of the medicine) or to other murine proteins - active or latent tuberculosis - acute or chronic hepatitis b - severe infections such as invasive fungal infections, bacterial sepsis, or abscesses - opportunistic infections (e.g. pneumocystosis, listeriosis) - moderate or severe heart failure (nyha class iii / iv) - immunosuppression (e.g. organ transplantation, aids, leukopenia) - malignancies or lymphoproliferative diseases or chemotherapy within the last 4 weeks - multiple sclerosis or peripheral demyelinating diseases, including the guillain-barré syndrome - treatment with other biologics for therapy for approved indications of infliximab (e.g. for rheumatoid arthritis, crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis) further

inclusion criteria: - age ≥ 18 years - infection with sars-cov-2 (virus detection by means of a pcr test not older than 72 hours) - bipulmonary infiltrates (detection by means of x-rays or computed tomography) - covid inflammation score ≥ 10 - ferritin concentration (serum or plasma) ≥ 500 ng / ml - arterial oxygen saturation ≤ 93% when breathing room air - written informed consent from the patient - potentially childbearing women: negative pregnancy test exclusion criteria (in medical history): contraindications study medication: - hypersensitivity to the active substance infliximab (or any of the other ingredients of the medicine) or to other murine proteins - active or latent tuberculosis - acute or chronic hepatitis b - severe infections such as invasive fungal infections, bacterial sepsis, or abscesses - opportunistic infections (e.g. pneumocystosis, listeriosis) - moderate or severe heart failure (nyha class iii / iv) - immunosuppression (e.g. organ transplantation, aids, leukopenia) - malignancies or lymphoproliferative diseases or chemotherapy within the last 4 weeks - multiple sclerosis or peripheral demyelinating diseases, including the guillain-barré syndrome - treatment with other biologics for therapy for approved indications of infliximab (e.g. for rheumatoid arthritis, crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis) further